PT - JOURNAL ARTICLE AU - Badano, María Noel AU - Duarte, Alejandra AU - Salamone, Gabriela AU - Sabbione, Florencia AU - Pereson, Matias AU - Chuit, Roberto AU - Baré, Patricia TI - Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children AID - 10.1101/2022.12.15.22283480 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.15.22283480 4099 - http://medrxiv.org/content/early/2022/12/16/2022.12.15.22283480.short 4100 - http://medrxiv.org/content/early/2022/12/16/2022.12.15.22283480.full AB - Vaccination against COVID-19 has mitigated the impact of SARS-CoV-2 infection, decreasing the probability of progression to severe disease and death in vaccinated people.Parallel to the development and administration of COVID-19 vaccines, the immune response induced by the different vaccine platforms has been investigated, mainly, in the adult population. However, since the approval of the vaccines for use in pediatric individuals was a posteriori, vaccination began later in this population. This, added to the difficulty in obtaining blood samples from pediatric individuals, has led to less knowledge about the humoral immune response following vaccination in children.In this work, we analyzed the humoral response induced by vaccination in children through a non-invasive approach such as the measurement of specific salivary antibodies. Our results showed a high prevalence of specific salivary antibodies (81%), with the highest levels of antibodies being observed in those children who had three doses, a greater number of exposures and a shorter interval time between the last exposure to SARS-CoV-2 antigens and saliva collection. These results agree with those reported for the systemic humoral immune response in vaccinated adults, suggesting the administration of booster doses in children to maintain high antibody levels.Therefore, determination of salivary antibodies against SARS-CoV-2 could be a non-invasive tool for disease surveillance, vaccination follow-up and to assist vaccination strategies against COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors thank all the children enrolled in this study and their parents for their participation and collaboration. Some aspects of this work could not have been fulfilled without the generous contribution of the IIHEMA, IIE and Academia Nacional de Medicina who provide financial support to our ongoing research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Academia Nacional de Medicina gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors(BAU/mL)binding antibody units (BAU) per mL(GMC)geometric mean concentrations(95% CI)95% confidence intervals